News|Articles|September 1, 2016

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-09-07-2016
  • Volume 11
  • Issue 9

Automated Infrared Microscope Effectively Analyzes Micro Samples

The AIM-9000 infrared microscope contains automated analysis functions and a wide-field camera option.

On August 24, 2016, Shimadzu Scientific Instruments (SSI) announced the release of the AIM-9000 infrared microscope. With automated analysis functions and a wide-field camera option, the microscope enables analysts to observe, measure, and analyze micro samples. Laboratories can use this microscope system to perform high-sensitivity analysis in fields such as electrical/electronics, forensics, pharmaceuticals, life science, foods, and chemicals.

In addition to observing large areas up to 10x13 mm, analysts can use the wide field camera and microscope camera together to zoom and position areas as small as 30x40 μm without loss or repositioning of the sample. The microscope has a 30,000:1 signal-to-noise ratio which allows users to obtain spectra from small contaminants for library matching and identification.

The microscope also features automatic contaminant recognition and registration. The microscopes software automatically selects potential areas for analysis and suggests optimal aperture sizes and angles. The user can then select all for analysis, select none, or add their own manually with a mouse click-and-drag operation. All selected sample images are saved into the measured spectral file.

The system contains a visible/infrared dual view system. This allows users to measure infrared spectra while simultaneously checking a visible image of the sample. This provides for more confident measurements and decreases measurement time. Analysts can also use the high-speed mapping program, which captures microscope images and synthesizes them to create visual images for large areas.

Source: Shimadzu Scientific Instruments


Related to this article

PharmTech Weekly Roundup—October 2, 2026
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Regulatory Roundup—September 2026
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.